INITIAL FUNDING, RFP #N02-CM-37002-05, DTP-13-015, 02/01/2013 - 01/31/2014, SHE

初始资金、RFP

• 批准号: 9201221
• 负责人: JONATHAN WHITE, PHD
• 金额: $ 35.09万
• 依托单位: MIDWEST RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-02-01 至 2018-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9201221
• 关键词: Academia; Biological Markers; Clinical Trials; Diagnosis; Division of Cancer Treatment and Diagnosis; Dosage Forms; Evaluation; Funding; Imaging Techniques; Industry; Life; Malignant Neoplasms; National Cancer Institute; Play; Role; Running; Staging; Support Contracts; Therapeutic; Work; cancer diagnosis; cancer imaging; cancer therapy; drug discovery; image guided; image guided therapy; member; novel diagnostics; novel therapeutics

The Division of Cancer Treatment and Diagnosis (DCTD) focuses its activities on developing novel diagnostics and therapies for cancer. DCTD staff members, along with colleagues throughout the National Cancer Institute (NCI), academia, and industry, are working to generate a seamless pipeline of biomarkers and therapeutics that runs the gamut from initial efforts in drug discovery through late-stage clinical trials. New cancer imaging techniques play a critical role in support of this pipeline as advances in image-guided diagnosis and image-guided therapies continue to emerge.

癌症治疗和诊断（DCTD）的分裂将其活动集中在开发新的诊断和癌症疗法上。 DCTD的工作人员以及全国癌症研究所（NCI），学术界和工业的同事们都在努力生成无缝的生物标志物和治疗剂管道，这些管道从药物发现的最初努力到后期临床试验从最初的努力进行。随着图像引导的诊断和图像引导的疗法的进步继续出现，新的癌症成像技术在支持该管道方面起着至关重要的作用。